Skip to content
All resources

GLP-1 and metabolic

Tirzepatide Side Effects: What SURPASS and SURMOUNT Recorded

AM

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 10 sections
  1. Where do these numbers come from?
  2. What are the most common side effects of tirzepatide?
  3. How many people stopped tirzepatide because of side effects?
  4. Does tirzepatide cause low blood sugar?
  5. Does tirzepatide cause gallbladder problems?
  6. Does tirzepatide cause pancreatitis?
  7. What about thyroid cancer?
  8. What do the trials not cover?
  9. Where is the official Canadian safety information?
  10. Frequently asked questions

Across the SURPASS trials in type 2 diabetes, the most common tirzepatide side effects were nausea (12–24%), diarrhoea (12–22%) and vomiting (2–13%), mostly mild to moderate and concentrated during dose escalation. In the SURMOUNT obesity trials, gastrointestinal events affected 27.8% to 72.8% of tirzepatide recipients against 12.2% to 32.5% on placebo. Meta-analyses of randomised trials find more gallbladder and biliary events with tirzepatide. Acute pancreatitis was rare, at 0.22% across 19 trials, with no clear dose-response. Tirzepatide is an authorised medicine in Canada.

A translucent model of the digestive system with the gallbladder highlighted
Illustration: most reported events in these trials were gastrointestinal.

Where do these numbers come from?

Tirzepatide is Eli Lilly's dual GIP and GLP-1 receptor agonist. It has been studied in two large phase 3 programmes: SURPASS in type 2 diabetes, with HbA1c as the main endpoint, and SURMOUNT in obesity, with body weight as the main endpoint. Each trial records adverse events, every unfavourable medical occurrence during treatment whether or not the drug caused it, and compares their rates with a placebo or active comparator. The retatrutide side-effects article explains how adverse events are collected, coded and graded, and why the comparator column matters as much as the drug column.

Everything below is drawn from published abstracts. Where an abstract gives no rate, none is quoted.

What are the most common side effects of tirzepatide?

Gastrointestinal events dominate, as they do for every drug acting at the GLP-1 receptor.

SourcePopulationWhat it reported
SURPASS-2 (1,879 participants, 40 weeks)Type 2 diabetes; tirzepatide vs semaglutideNausea 17–22% vs 18%; diarrhoea 13–16% vs 12%; vomiting 6–10% vs 8%
Pooled SURPASS-1 to -5 (6,263 participants)Type 2 diabetes; various comparatorsNausea 12–24%; diarrhoea 12–22%; vomiting 2–13%; transient, mild to moderate
SURMOUNT-1 (2,539 participants, 72 weeks)Obesity without diabetes; placeboMostly mild to moderate, mainly during dose escalation
Pooled SURMOUNT-1 to -4Obesity with or without diabetes; placeboAny GI event 27.8–72.8% vs 12.2–32.5%

The ranges span dose levels and trials, so they are not a single risk figure. The pooled SURMOUNT analysis found that most gastrointestinal events were non-serious and occurred during escalation. Where anti-diarrhoeal or anti-nausea medicines were used, they were first used most often in that period too.

A common suspicion is that the weight loss is simply a product of nausea. The pooled analyses tested this directly. In SURPASS, weight reduction was similar whether or not participants reported nausea, vomiting or diarrhoea. In SURMOUNT, mediation analysis suggested those events accounted for up to 3.1% of total weight reduction. Gastrointestinal effects contribute slightly. They do not explain the effect.

How many people stopped tirzepatide because of side effects?

In SURMOUNT-1, adverse events led to treatment discontinuation in 4.3%, 7.1% and 6.2% of participants across the three tirzepatide groups, against 2.6% on placebo. Across SURMOUNT-1 to -4, between 1.0% and 10.5% of tirzepatide recipients stopped because of gastrointestinal events specifically. Note the shape in SURMOUNT-1: the middle dose group had the highest discontinuation, not the highest dose group. Escalation schemes, chance and who drops out early all shape that figure.

Serious adverse events, those causing death, hospitalisation or lasting harm, occurred in 5% to 7% of tirzepatide recipients and 3% of semaglutide recipients in SURPASS-2. A single trial cannot say whether that difference is real. The tirzepatide vs semaglutide article covers that head-to-head in full.

Does tirzepatide cause low blood sugar?

Rarely, in the trials summarised here. In SURPASS-2, glucose below 54 mg/dL was recorded in 0.2% to 1.7% of tirzepatide recipients against 0.4% on semaglutide. The picture can change when tirzepatide is combined with other glucose-lowering drugs that cause hypoglycaemia themselves, such as insulin. Those combinations are addressed in the product monograph rather than in these abstracts.

Does tirzepatide cause gallbladder problems?

The randomised evidence says gallbladder and biliary events are more frequent with tirzepatide, though still uncommon in absolute terms.

Meta-analysisTrials and participantsFinding
Zeng et al., 20239 trials, 9,871 participantsComposite gallbladder or biliary disease vs placebo or basal insulin: RR 1.97 (95% CI 1.14 to 3.42)
Gong et al., 202512 trials, 12,351 participantsGallbladder or biliary disease: RR 1.52 (1.17 to 1.98); cholelithiasis: RR 1.67 (1.14 to 2.44); no dose-response

A relative risk of about 1.5, the measure explained in the study design guide, means the event was about half again as frequent as in the comparison groups, not that it was common. The meta-analyses report relative risks in their abstracts rather than absolute rates. Rapid weight loss itself raises gallstone risk, regardless of how it is achieved. The trials cannot fully separate a drug effect from a weight-loss effect. For clinical decisions, that distinction matters less than the fact that the risk is real.

Does tirzepatide cause pancreatitis?

This is the most persistent question for the incretin class. The randomised data so far do not show a clear signal for tirzepatide, but they cannot exclude a small one.

Zeng and colleagues found no significant association: RR 1.46, with a 95% confidence interval from 0.59 to 3.61. An interval that wide is compatible with a lower risk, with no difference, or with a risk more than three times higher. Benny and colleagues pooled 19 randomised trials with 15,471 participants. Acute pancreatitis occurred in 0.22%, with no significant difference between dose levels. They noted that all the trials were industry-funded, follow-up was short to moderate, and precision was limited.

Spontaneous reporting systems add a different, weaker kind of evidence. A disproportionality analysis of the US FDA Adverse Event Reporting System by Wu and colleagues found more pancreatic and biliary reports than expected for tirzepatide and for GLP-1 receptor agonists. But metformin and SGLT2 inhibitors, used as comparison drugs, also showed pancreatic signals. The authors state that such signals cannot estimate incidence or prove causation. They flag questions for proper cohort studies to answer.

What about thyroid cancer?

Thyroid cancer has long been a debated question for the incretin class, with conflicting observational findings. A 2026 meta-analysis by Eisa and Barood pooled 15 randomised trials of approved incretin-based therapies, with 84,237 participants. There were 28 thyroid cancers in the treated groups and 15 in the control groups: odds ratio 1.52, 95% CI 0.86 to 2.68, not statistically significant. The authors rated the certainty of the evidence very low because of imprecision, and said the data cannot exclude a clinically relevant increase. With 43 events in total, that is the honest conclusion.

What do the trials not cover?

Hair loss. It appears in the prescribing information rather than in the trial abstracts. It is covered in GLP-1 hair loss: what the trials report.

Muscle and lean mass. Body-composition substudies are discussed in GLP-1 muscle loss and lean mass.

Cardiovascular events. These need a dedicated outcomes trial, covered in tirzepatide cardiovascular outcomes. Its trials in sleep apnoea are covered in tirzepatide and obstructive sleep apnea.

Rare and long-term harms. Trials of a year or two in screened volunteers are not built to find these. That is the job of post-marketing surveillance.

Where is the official Canadian safety information?

Tirzepatide is authorised in Canada under the brand name Mounjaro, for type 2 diabetes and for chronic weight management. The authoritative statement of its warnings, precautions, contraindications and adverse reactions is the Mounjaro product monograph, published by Eli Lilly Canada and reviewed by Health Canada. It can be found through the product's entry in Health Canada's Drug Product Database. Monographs are revised as new safety information emerges. The current version supersedes any summary, this one included.

Supplied here for laboratory use: Tirzepatide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Research-grade tirzepatide is a laboratory reagent, not Mounjaro; the distinction is set out in the Canadian peptide rules article. The trial safety record describes the licensed product given to screened participants under monitoring. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

What is the most common side effect of tirzepatide? Nausea, followed by diarrhoea, vomiting and constipation. Across the SURPASS diabetes trials, nausea affected 12% to 24% of tirzepatide recipients, diarrhoea 12% to 22% and vomiting 2% to 13%. Most events were mild to moderate, transient, and concentrated during dose escalation rather than spread evenly through treatment.

Do tirzepatide side effects go away? In the trials, gastrointestinal events clustered during dose escalation and were mostly transient. The pooled SURMOUNT analysis found that most were non-serious and that anti-nausea and anti-diarrhoeal medicines were first used mostly in that early period. Trials describe group patterns, though. They do not predict any one person's course.

Is pancreatitis a proven side effect of tirzepatide? Not on current randomised evidence. A meta-analysis of 19 trials found acute pancreatitis in 0.22% of participants, with no dose-response. Another found no significant increase, but with a wide confidence interval. Spontaneous-report signals exist for the whole class and cannot establish causation. A small increase has not been ruled out.

Does tirzepatide raise the risk of gallstones? Meta-analyses of randomised trials found gallbladder or biliary disease about one and a half to two times as frequent with tirzepatide as with comparators, and cholelithiasis specifically about 1.7 times as frequent. Absolute rates remained low. Rapid weight loss raises gallstone risk by itself, which the trials cannot fully separate from a drug effect.

Where can I find tirzepatide's official side-effect list in Canada? In the Mounjaro product monograph, published by Eli Lilly Canada and reviewed by Health Canada. It is linked from the product's entry in the Drug Product Database. The monograph contains the full adverse-reaction tables, warnings and contraindications, and is updated as new information emerges, so check the current version.

Selected Research References

  1. Frías JP, Davies MJ, Rosenstock J, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. pubmed.ncbi.nlm.nih.gov/34170647
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. pubmed.ncbi.nlm.nih.gov/35658024
  3. Patel H, Khunti K, Rodbard HW, et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, Obesity and Metabolism. 2024;26(2):473-481. pubmed.ncbi.nlm.nih.gov/37853960
  4. Rubino DM, Pedersen SD, Connery L, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity and Metabolism. 2025;27(4):1826-1835. pubmed.ncbi.nlm.nih.gov/39789843
  5. Zeng Q, Xu J, Mu X, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14:1214334. pubmed.ncbi.nlm.nih.gov/37908750
  6. Gong J, Gao F, Jiang K, et al. Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis. Journal of Diabetes Investigation. 2025;16(1):83-92. pubmed.ncbi.nlm.nih.gov/39569606
  7. Benny O, Agarwal A, Alecock H, et al. Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials. Pancreatology. 2026;26(4):552-565. pubmed.ncbi.nlm.nih.gov/41927408
  8. Wu Y, Li K, Wang Y, et al. Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports. Frontiers in Endocrinology. 2026;17:1941948. pubmed.ncbi.nlm.nih.gov/42865361
  9. Eisa N, Barood O. Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. AACE Endocrinology and Diabetes. 2026;13(3):400-409. pubmed.ncbi.nlm.nih.gov/42221413

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.